Roche – Sponsored Industry Symposium

How could treatment practice change with cancer immunotherapy combinations in patients with HCC?

Friday 11 September 2020, 14.00–15.00 CET

After relying on only tyrosine kinase inhibitors in first-line systemic therapy for unresectable HCC for over a decade, a number of trials of novel cancer immunotherapy combinations have shown improved outcomes for patients with HCC. These emerging positive clinical trial data have contributed to a rapidly evolving treatment landscape in unresectable HCC, with implications for clinical practice.

As such, we are delighted to present our Roche-sponsored Virtual Industry Partner Symposium, How could treatment practice change with cancer immunotherapy combinations in patients with HCC?, as part of the ILCA 2020 virtual programme. In this symposium, our esteemed panel will give an overview of the evolving treatment landscape for HCC, review the most recent data for cancer immunotherapy combinations and, crucially, provide expert insights and guidance on how their safety profiles can be navigated. With the ongoing expansion of the HCC armamentarium, we will also discuss what clinicians need to know in order to make informed and tailored treatment decisions for their patients.

We are excited to conclude our symposium with discussion of a patient case and an interactive Q&A session. Considering the broad attendance of ILCA, we invite you to participate in what is sure to be an engaging, meaningful and multidisciplinary dialogue!

On behalf of the faculty, I look forward to welcoming you to this virtual symposium.

Yours sincerely,

Peter Galle


Time Presentation Faculty
14.00–14.02 Welcome and introductions Peter Galle
14.02–14.10 Navigating the shifting treatment patterns for HCC Jian Zhou
14.10–14.20 Understanding the latest efficacy data for unresectable HCC Peter Galle
14.20–14.35 Discussing safety with cancer immunotherapy combinations Bruno Sangro
14.35–14.45 Making the correct clinical decisions: what do we need to know? Riccardo Lencioni
14.45–15.00 Reviewing a patient case: who are the right patients for cancer immunotherapy combinations? All faculty

Meet the Faculty

Jian Zhou

Jian Zhou is Director of the Liver Surgery & Transplantation department at Zhongshan Hospital and has worked in the field of liver cancer for 29 years. He has been in charge of 23 research projects and has published 78 SCI papers as first or corresponding author. His research focuses on the early diagnosis, prevention and treatment of recurrence and metastasis of HCC.

Peter Galle

Peter Galle is Chief Physician of the Department of Gastroenterology and Hepatology at University Medical Centre Mainz, and has served as co-editor for the Journal of Hepatology. His research focuses on hepatic apoptotic cell death, immune escape of tumour cells, and clinical and molecular aspects of HCC. He is the current President of the German Association for the Study of the Liver (GASL).

Bruno Sangro

Bruno Sangro is Director of the Liver Unit and Co-Director of the HPB Oncology Area at Clínica Universidad de Navarra. He is actively involved in research focused on therapeutic innovation in the field of liver cancer, and currently serves as President
of ILCA.

Riccardo Lencioni

Riccardo Lencioni is an Honorary Research Professor of Interventional Oncology at the Miami Cancer Institute. He is a leading member of several expert panels and has co-authored numerous white papers. He is also an Associate Editor of Liver Cancer.

Roche’s commitment to research in GI tumours

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Patients with HCC have two diseases in one organ: firstly, the underlying liver disease and, secondly, the HCC tumour. Both liver diseases cause a significant burden for the patient and may impact associated treatment. Together with partners, Roche aims to stop the progression of chronic liver disease and, one day, even cure HCC with interventions across detection, prevention and treatment. By rethinking the disease from every possible angle and developing integrated solutions, this new era of partnership and innovation can improve the lives of millions of people around the world.